Akoustis Technologies Ord Shs
AKTS19.000USD
+0.020+0.11%
收盘 02/09, 16:00（美东）报价延迟15分钟
2.34B总市值
亏损市盈率 TTM
关于 Akoustis Technologies Ord Shs 公司
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shs简介
公司代码AKTS
公司名称Aktis Oncology Inc
上市日期Jan 09, 2026
CEORoden (Matthew)
员工数量117
证券类型Ordinary Share
年结日Jan 09
公司地址17 Drydock Avenue
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02210
电话13026587581
网址https://www.aktisoncology.com/
公司代码AKTS
上市日期Jan 09, 2026
CEORoden (Matthew)
Akoustis Technologies Ord Shs公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
+91998.00%
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
+2103.00%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ms. Jill K. Frizzley
Ms. Jill K. Frizzley
Independent Director
Independent Director
--
--
Mr. Matthew R. Kahn, CPA
Mr. Matthew R. Kahn, CPA
Independent Director
Independent Director
--
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
+91998.00%
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
+2103.00%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
收入明细
单位: USD更新时间: 1月10日 周六
单位: USD更新时间: 1月10日 周六
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Asia
5.84M
64.74%
Americas
2.43M
26.95%
Europe
750.00K
8.31%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 2月5日 周四
更新时间: 2月5日 周四
持股股东
股东类型
持股股东
持股股东
占比
MPM BioImpact LLC
20.26%
Eli Lilly and Company
12.53%
VV Manager LLC
11.51%
EcoR1 Capital, LLC
9.53%
Feldman (Paul L. Ph.D.)
0.23%
其他
45.95%
持股股东
持股股东
占比
MPM BioImpact LLC
20.26%
Eli Lilly and Company
12.53%
VV Manager LLC
11.51%
EcoR1 Capital, LLC
9.53%
Feldman (Paul L. Ph.D.)
0.23%
其他
45.95%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
29.78%
Corporation
12.53%
Venture Capital
11.51%
Individual Investor
0.42%
其他
45.76%
机构持股
更新时间: 1月10日 周六
更新时间: 1月10日 周六
报告期
机构数
持股数
持股占比
持股变动
2026Q1
177
54.73K
0.04%
-32.32M
2025Q4
188
74.33K
0.05%
-32.41M
2025Q3
209
74.33K
0.05%
-35.90M
2025Q2
236
74.33K
0.05%
-41.95M
2025Q1
251
315.89K
0.20%
-42.44M
2024Q4
266
839.61K
0.54%
-43.07M
2024Q3
283
21.16M
13.70%
-24.03M
2024Q2
288
25.38M
23.18%
-30.85M
2024Q1
283
43.24M
43.52%
-1.29M
2023Q4
287
31.11M
40.06%
-14.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
暂无数据
查看更多
持股ETF
更新时间: 1月10日 周六
更新时间: 1月10日 周六
机构名称
占比
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Russell 3000 ETF
占比0%
Global X Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
